Announcements
- aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
- aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
- aTyr Pharma to Present at Upcoming Investor Conferences
- aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
- aTyr Pharma to Participate in April Investor Conferences
- aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
- aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
- aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
More ▼
Key statistics
As of last trade, aTyr Pharma Inc (471A:FRA) traded at 1.39, 41.12% above the 52 week low of 0.985 set on Nov 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.39 |
---|---|
High | 1.39 |
Low | 1.39 |
Bid | 1.40 |
Offer | 1.48 |
Previous close | 1.38 |
Average volume | 511.11 |
---|---|
Shares outstanding | 69.01m |
Free float | 67.20m |
P/E (TTM) | -- |
Market cap | 106.28m USD |
EPS (TTM) | -0.9029 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 07:04 BST.
More ▼